title: Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
abstract: Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: R-CHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.
authors: Nicolas
authors: N
authors: Mounier
authors: Josette
authors: J
authors: Briere
authors: Christian
authors: C
authors: Gisselbrecht
authors: Felix
authors: F
authors: Reyes
authors: Philippe
authors: P
authors: Gaulard
authors: Bertrand
authors: B
authors: Coiffier